6.jpg)
Daiichi Sankyo Company, Limited has announced that its generics subsidiary, Daiichi Sankyo Espha Co will launch in Japan 4 new generic drugs with 2 active ingredients on December 8, 2017, that were announced in the official gazette.
The products, a HMG-CoA reductase inhibitor rosuvastatin OD tablets 2.5 mg & 5 mg “DSEP”(Crestor OD tablets), and anti-herpes virus agent, famciclovir tablets 250 mg/500 mg “DSEP” (Famvir tablets).
Rosuvastatin OD tablets “DSEP” are authorized generics (AG) of Crestor OD Tablets and will be additional formulations with the same ingredient to rosuvastatin Tablets 2.5 mg “DSEP” and rosuvastatin tablets 5 mg “DSEP” currently sold by Daiichi Sankyo Espha. The launch of the OD tablets will be same line with the original brand product regarding available formulations and specifications.
Daiichi Sankyo Espha has achieved formulation and labeling innovations. They will reduce the burden on the pharmacist in checks to prevent medication dispensing errors and avoid medical accidents such as patients taking the wrong medicine by mistake.
Daiichi sankyo espha to introduce four, generic drugs in japan
